Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "Peptide Therapeutics Market Size, Share & Trends Analysis Report by Application, Type (Innovative, Generic), Type of Manufacturer (Inhouse, Outsourced), Route of Administration, Synthesis Technology, and Region with Growth Forecasts, 2025-2030" has been added to ResearchAndMarkets.com's offering.
The Peptide Therapeutics Market was valued at USD 117.26 billion in 2024, and is projected to reach USD 260.25 billion by 2030, rising at a CAGR of 10.77%. It is expected to grow at a CAGR of 10.77% from 2025 to 2030.
The increasing demand for efficient and rapid-acting therapeutics for the treatment of cancer and other lifestyle-associated disorders, which result in lesser adverse effects, is anticipated to propel market growth. The rising incidence of cancer calls for exploring and introducing other means of therapies and low-cost treatment alternatives is expected to drive the market. Moreover, the growing geriatric population is expected to widen the consumer base by triggering the incidence rate of target diseases such as cancer and diabetes, which is expected to drive the demand for peptide therapeutics.
Peptide Therapeutics Market Report Highlights
- By type, the generic segment is the second largest segment in the market. The rise of generic peptide therapeutics is an emerging trend in the pharmaceutical industry.
- Outsourcing manufacturing segment is anticipated to grow at the fastest CAGR during the forecast period owing to the requirements of complex procedures and a shift in preference toward outsourcing, which helps in eliminating the cost of production.
- Based on synthesis technology, the recombinant DNA technology segment accounted for the largest revenue share of 79.26% in 2024.
- The North America Peptide Therapeutics market maintained a leading position in 2024 with share of 60.21%, driven by the rising prevalence of cancer, metabolic disorders and rare diseases.
This report addresses:
- Market intelligence to enable effective decision-making.
- Market estimates and forecasts from 2018 to 2030.
- Growth opportunities and trend analyses.
- Segment and regional revenue forecasts for market assessment.
- Competition strategy and market share analysis.
- Product innovation listings for you to stay ahead of the curve.
- COVID-19's impact and how to sustain in this fast-evolving market.
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Key Topics Covered
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Peptide Therapeutics Market Variables, Trends, & Scope
3.1. Parent Market Outlook
3.2. Ancillary Market Outlook
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.1.1. Increasing Prevalence of Cancer
3.3.1.1.1. Cancer Incidence Data
3.3.1.2. Technological Advancements
3.3.1.3. Presence of Strong Product Pipeline
3.3.2. Market Restraints Analysis
3.3.2.1. Increasing Complexity of Peptides
3.3.2.2. High Cost of Manufacturing Equipment
3.4. Peptide Therapeutics Analysis Tools
3.4.1. Porter's Analysis
3.4.2. PESTEL Analysis
3.5. Pipeline Analysis
3.5.1. Phase 1
3.5.2. Phase 2
3.5.3. Phase 3
3.6. Phase 3 Pipeline Drug Forecasts
3.7. Case Studies Analysis
Chapter 4. Peptide Therapeutics Market: By Application Estimates & Trend Analysis
4.1. Peptide Therapeutics Market: Application Segment Dashboard
4.2. Peptide Therapeutics Market: by Application Movement Analysis, 2024 & 2030 (USD Million)
4.3. Metabolic Disorders
4.4. Cancer
4.5. Neurological Disorders
4.6. Gastrointestinal Disorders
4.7. Cardiovascular Disorders
4.8. Pain
4.9. Infectious Disease
4.10. Renal Disorders
4.11. Dermatological Disorders
4.12. Respiratory Disorders
4.13. Others
Chapter 5. Peptide Therapeutics Market: Type Estimates & Trend Analysis
5.1. Peptide Therapeutics Market: Type Segment Dashboard
5.2. Peptide Therapeutics Market: by Type Movement Analysis, 2024 & 2030 (USD Million)
5.3. Innovative
5.4. Generic
Chapter 6. Peptide Therapeutics Market: Type of Manufacturer Estimates & Trend Analysis
6.1. Peptide Therapeutics Market: Type of Manufacturer Segment Dashboard
6.2. Peptide Therapeutics Market: by Type of Manufacturer Movement Analysis, 2024 & 2030 (USD Million)
6.3. Inhouse
6.4. Outsourced
Chapter 7. Peptide Therapeutics Market: Synthesis Technology Estimates & Trend Analysis
7.1. Peptide Therapeutics Market: Synthesis Technology Segment Dashboard
7.2. Peptide Therapeutics Market: Synthesis Technology Movement Analysis, 2024 & 2030 (USD Million)
7.3. Recombinant DNA Technology
7.4. Solid-Phase Peptide Synthesis (SPPS)
7.5. Hybrid
7.6. Liquid-Phase Peptide Synthesis (LPPS)
7.7. Others
Chapter 8. Peptide Therapeutics Market: Route of Administration Estimates & Trend Analysis
8.1. Peptide Therapeutics Market: Route of Administration Segment Dashboard
8.2. Peptide Therapeutics Market: Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
8.3. Parenteral Route
8.4. Oral Route
8.5. Mucosal
8.6. Pulmonary
8.7. Others
Chapter 9. Peptide Therapeutics Market: Regional Estimates & Trend Analysis
9.1. Peptide Therapeutics Market Share, by Region, 2024 & 2030, USD Million
9.2. North America
9.3. Europe
9.4. Asia-Pacific
9.5. Latin America
9.6. Middle East and Africa
Chapter 10. Competitive Landscape
10.1. Recent Developments & Impact Analysis by Key Market Participants
10.2. Company Categorization
10.3. Participant Overview
10.4. Financial Performance
10.5. Product Bench Marking
10.6. Company Market Share Analysis, 2024
10.7. Company Profiles
10.7.1. Eli Lilly and Company
10.7.2. Pfizer Inc.
10.7.3. Amgen Inc.
10.7.4. Takeda Pharmaceutical Company Limited
10.7.5. AstraZeneca
10.7.6. Teva Pharmaceutical Industries Ltd.
10.7.7. Sanofi
10.7.8. F. Hoffmann-La Roche Ltd.
10.7.9. Novartis AG
10.7.10. Novo Nordisk A/S
10.7.11. GSK plc
10.7.12. Ironwood Pharmaceuticals Inc.
10.7.13. Radius Health Inc. (Subsidiary of Gurnet Point Capital and Patient Square Capital)
10.7.14. Ipsen Pharma
Chapter 11. Conclusion/Key Takeaways/KoL Insights
For more information about this report visit https://www.researchandmarkets.com/r/9ytz1o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
